CA2379608A1 - Traitements et diagnostics du cancer utilisant des molecules et procedes en rapport avec le rad51 - Google Patents

Traitements et diagnostics du cancer utilisant des molecules et procedes en rapport avec le rad51 Download PDF

Info

Publication number
CA2379608A1
CA2379608A1 CA002379608A CA2379608A CA2379608A1 CA 2379608 A1 CA2379608 A1 CA 2379608A1 CA 002379608 A CA002379608 A CA 002379608A CA 2379608 A CA2379608 A CA 2379608A CA 2379608 A1 CA2379608 A1 CA 2379608A1
Authority
CA
Canada
Prior art keywords
rad51
cancer
cell
level
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002379608A
Other languages
English (en)
Inventor
Horst-Werner Sturzbecher
Gurucharan Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pangene Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/454,495 external-priority patent/US6576759B2/en
Application filed by Individual filed Critical Individual
Publication of CA2379608A1 publication Critical patent/CA2379608A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des procédés permettant, d'une part de traiter, de diagnostiquer et de pronostiquer le cancer, d'autre part de préparer le patient à un traitement anticancéreux, mais aussi de prédire l'issue de tels traitements, et enfin des procédés d'induction de l'apoptose. L'invention concerne également des compositions, des agents et des nécessaires correspondants.
CA002379608A 1999-08-10 2000-08-10 Traitements et diagnostics du cancer utilisant des molecules et procedes en rapport avec le rad51 Abandoned CA2379608A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US14809299P 1999-08-10 1999-08-10
US14809199P 1999-08-10 1999-08-10
US60/148,092 1999-08-10
US60/148,091 1999-08-10
US15461699P 1999-09-17 1999-09-17
US60/154,616 1999-09-17
US45530099A 1999-12-06 1999-12-06
US09/455,300 1999-12-06
US09/454,495 US6576759B2 (en) 1999-02-10 1999-12-06 Antisense inhibition of RAD51
US09/454,495 1999-12-06
PCT/US2000/022077 WO2001011369A1 (fr) 1999-08-10 2000-08-10 Traitements et diagnostics du cancer utilisant des molecules et procedes en rapport avec le rad51

Publications (1)

Publication Number Publication Date
CA2379608A1 true CA2379608A1 (fr) 2001-02-15

Family

ID=27538317

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002379608A Abandoned CA2379608A1 (fr) 1999-08-10 2000-08-10 Traitements et diagnostics du cancer utilisant des molecules et procedes en rapport avec le rad51

Country Status (5)

Country Link
EP (1) EP1204868A1 (fr)
JP (1) JP2003506100A (fr)
AU (1) AU6767300A (fr)
CA (1) CA2379608A1 (fr)
WO (1) WO2001011369A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393250B2 (en) 2012-04-12 2016-07-19 University Of Saskatchewan Phthalocyanine compounds useful as RecA inhibitors and methods of using same

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013488A2 (fr) * 2001-08-09 2003-02-20 Pangene Corporation Procedes et compositions visant a inhiber rad51
AU2007340129B2 (en) * 2006-12-26 2012-02-02 Pharmacyclics Llc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
WO2008156827A2 (fr) * 2007-06-20 2008-12-24 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procédés de détermination du stade moléculaire
US8188252B2 (en) * 2008-11-17 2012-05-29 University Of Rochester Rad51 derived cancer cell specific promoters for targeted anti-cancer therapy
RU2609833C2 (ru) 2011-09-13 2017-02-06 Фармасайкликс Элэлси Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
EP3502700A1 (fr) * 2017-12-21 2019-06-26 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Procédés basés sur la détection de foyers rad51 dans des cellules tumorales

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037125A (en) * 1996-11-05 2000-03-14 Lexicon Genetics Incorporated Disruption of the mammalian RAD51 protein and disruption of proteins that associate with mammalian RAD51 for hindering cell proliferation and/or viability of proliferating cells
WO1998034118A1 (fr) * 1997-01-30 1998-08-06 Yale University Methodes diagnostiques et compositions basees sur la repartition de rad51

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393250B2 (en) 2012-04-12 2016-07-19 University Of Saskatchewan Phthalocyanine compounds useful as RecA inhibitors and methods of using same

Also Published As

Publication number Publication date
WO2001011369A8 (fr) 2001-04-05
EP1204868A1 (fr) 2002-05-15
WO2001011369A1 (fr) 2001-02-15
AU6767300A (en) 2001-03-05
JP2003506100A (ja) 2003-02-18

Similar Documents

Publication Publication Date Title
Gu et al. Regulation of XIAP translation and induction by MDM2 following irradiation
Corn et al. Mxi1 is induced by hypoxia in a HIF-1–dependent manner and protects cells from c-Myc-induced apoptosis
EP2334791B1 (fr) Procédé pour la lutte contre la métastase cancéreuse ou la migration de cellules cancéreuses par modulation du taux cellulaire de lysyl-arnt synthétase
EP1856247B1 (fr) Régulation de l'autophagie et de la survie cellulaire
Bicknell et al. Forced expression of the cyclin B1–CDC2 complex induces proliferation in adult rat cardiomyocytes
US8067473B2 (en) Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors
Ray et al. Regulation of EGFR protein stability by the HECT-type ubiquitin ligase SMURF2
AU2006228990B8 (en) A method of diagnosis and treatment and agents useful for same
Shao et al. Abrogation of Chk1-mediated S/G2 checkpoint by UCN-01 enhances area-C-induced cytotoxicity in human colon cancer cells
Zhang et al. Hypoxic preconditioning protects cardiomyocytes against hypoxia/reoxygenation-induced cell apoptosis via sphingosine kinase 2 and FAK/AKT pathway
Bollaert et al. HBP1 phosphorylation by AKT regulates its transcriptional activity and glioblastoma cell proliferation
Wang et al. Silencing of TPD52 inhibits proliferation, migration, invasion but induces apoptosis of pancreatic cancer cells by deactivating Akt pathway.
CA2379608A1 (fr) Traitements et diagnostics du cancer utilisant des molecules et procedes en rapport avec le rad51
US20070037202A1 (en) Potentiation of cancer therapies by ZNF217 inhibition
Chen et al. Expression of SGTA correlates with neuronal apoptosis and reactive gliosis after spinal cord injury
Chen et al. Mitochondrial ribosomal protein S36 delays cell cycle progression in association with p53 modification and p21WAF1/CIP1 expression
CA2408297A1 (fr) Diagnostic du cancer et tests de criblage d'agents anticancereux
JP6494112B2 (ja) アストリンとラプターの相互作用調節因子、及びその癌治療での用途
WO2011129427A1 (fr) Agent de diagnostic et agent thérapeutique pour les cancers
Fish et al. Evidence for serpinB2-independent protection from TNF-α-induced apoptosis
Li et al. Higher LRRFIP1 expression in glioblastoma multiforme is associated with better response to teniposide, a type II topoisomerase inhibitor
Wang et al. Knock-down of ABCE1 gene induces G1/S arrest in human oral cancer cells
CA2751977A1 (fr) C-cbl et ses antagonistes pour le traitement et le diagnostic du cancer
CA2656577A1 (fr) Methode pour evaluer un cancer
Liu et al. PHB2 binds to ERβ to induce the autophagy of porcine ovarian granulosa cells through mTOR phosphorylation

Legal Events

Date Code Title Description
FZDE Dead